Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs
Objective: To assess prevalence of hyperlipidemia in patients receiving lopinavir boosted with ritonavir (LPV/r) and atazanavir boosted with ritonavir (ATV/r) antiretroviral drugs. Methods: HIV-infected patients (300) were recruited in the study between December 2015 and April 2016. Lipid profile in...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-04-01
|
Series: | Journal of the International Association of Providers of AIDS Care |
Online Access: | https://doi.org/10.1177/2325958219841908 |
id |
doaj-707e7faa51d7497ea3d007626a8e034b |
---|---|
record_format |
Article |
spelling |
doaj-707e7faa51d7497ea3d007626a8e034b2020-11-25T04:01:11ZengSAGE PublishingJournal of the International Association of Providers of AIDS Care2325-95822019-04-011810.1177/2325958219841908Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral DrugsEsther Muya MPharm0Appolinary Kamuhabwa PhD1 Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, TanzaniaObjective: To assess prevalence of hyperlipidemia in patients receiving lopinavir boosted with ritonavir (LPV/r) and atazanavir boosted with ritonavir (ATV/r) antiretroviral drugs. Methods: HIV-infected patients (300) were recruited in the study between December 2015 and April 2016. Lipid profile including triglycerides (TG), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (LDL-C) were assessed. Results: Prevalence of derangement in TG was 71.0% in patients using LPV/r compared to 44% in those using ATV/r ( P = .01). Use of LPV/r was independently associated with increased total cholesterol (TC; P = .001) and TG ( P = .0003). Females had raised levels of TC compared to males ( P = .00008). Body mass index of ≥ 25 kg/m 2 was also associated with raised TC ( P = .002) and LDL-C ( P = .006). Conclusion: LPV/r was significantly associated with lipid derangements, indicating the need to regularly monitor lipid profile in patients using LPV/r.https://doi.org/10.1177/2325958219841908 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Esther Muya MPharm Appolinary Kamuhabwa PhD |
spellingShingle |
Esther Muya MPharm Appolinary Kamuhabwa PhD Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs Journal of the International Association of Providers of AIDS Care |
author_facet |
Esther Muya MPharm Appolinary Kamuhabwa PhD |
author_sort |
Esther Muya MPharm |
title |
Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs |
title_short |
Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs |
title_full |
Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs |
title_fullStr |
Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs |
title_full_unstemmed |
Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs |
title_sort |
comparative assessment of the magnitude of hyperlipidemia in hiv-infected patients receiving lopinavir/r- and atazanavir/r-based antiretroviral drugs |
publisher |
SAGE Publishing |
series |
Journal of the International Association of Providers of AIDS Care |
issn |
2325-9582 |
publishDate |
2019-04-01 |
description |
Objective: To assess prevalence of hyperlipidemia in patients receiving lopinavir boosted with ritonavir (LPV/r) and atazanavir boosted with ritonavir (ATV/r) antiretroviral drugs. Methods: HIV-infected patients (300) were recruited in the study between December 2015 and April 2016. Lipid profile including triglycerides (TG), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (LDL-C) were assessed. Results: Prevalence of derangement in TG was 71.0% in patients using LPV/r compared to 44% in those using ATV/r ( P = .01). Use of LPV/r was independently associated with increased total cholesterol (TC; P = .001) and TG ( P = .0003). Females had raised levels of TC compared to males ( P = .00008). Body mass index of ≥ 25 kg/m 2 was also associated with raised TC ( P = .002) and LDL-C ( P = .006). Conclusion: LPV/r was significantly associated with lipid derangements, indicating the need to regularly monitor lipid profile in patients using LPV/r. |
url |
https://doi.org/10.1177/2325958219841908 |
work_keys_str_mv |
AT esthermuyampharm comparativeassessmentofthemagnitudeofhyperlipidemiainhivinfectedpatientsreceivinglopinavirrandatazanavirrbasedantiretroviraldrugs AT appolinarykamuhabwaphd comparativeassessmentofthemagnitudeofhyperlipidemiainhivinfectedpatientsreceivinglopinavirrandatazanavirrbasedantiretroviraldrugs |
_version_ |
1724447267395469312 |